Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Actinium Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ATNM
NYSE American
2836
www.actiniumpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- Nov 4th, 2024 12:30 pm
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
- Oct 18th, 2024 4:00 pm
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
- Sep 23rd, 2024 8:52 am
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
- Sep 20th, 2024 12:00 pm
Actinium: Q2 Earnings Snapshot
- Aug 5th, 2024 10:59 pm
Sector Update: Health Care Stocks Fall in Afternoon Trading
- Aug 5th, 2024 6:10 pm
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
- Aug 5th, 2024 11:00 am
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
- Aug 1st, 2024 12:00 pm
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
- Jul 25th, 2024 12:45 pm
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
- Jul 25th, 2024 11:30 am
3 Under-$10 Biotech Stocks That Could Make You Rich
- Jul 11th, 2024 6:23 pm
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
- Jul 2nd, 2024 9:05 pm
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
- Jun 20th, 2024 1:40 pm
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
- Jun 18th, 2024 12:45 pm
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
- Jun 17th, 2024 12:45 pm
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
- Jun 17th, 2024 12:00 pm
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
- Jun 14th, 2024 12:30 pm
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Jun 11th, 2024 12:30 pm
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
- Jun 10th, 2024 11:22 pm
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Jun 10th, 2024 12:30 pm
Scroll